Format

Send to

Choose Destination
Oncologist. 2010;15(11):1220-6. doi: 10.1634/theoncologist.2010-0162. Epub 2010 Nov 4.

Dexrazoxane as a cardioprotectant in children receiving anthracyclines.

Author information

1
Division of Oncology, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA. sepe@email.chop.edu

Abstract

Anthracyclines play a critical role in the treatment of a variety of childhood cancers. However, the cumulative cardiotoxic effects of anthracyclines limit the use of these agents in many treatment regimens. Dexrazoxane is a cardioprotectant that significantly reduces the incidence of adverse cardiac events in women with advanced breast cancer treated with doxorubicin-containing regimens. Clinical evidence for the efficacy of dexrazoxane as a cardioprotectant in children, especially from randomized clinical trials, is limited, but the available data support a short-term cardioprotective effect. Long-term follow-up in children treated with dexrazoxane has not been reported. Dexrazoxane's impact on the antitumor effect and toxicity profile of the anthracyclines and the role of dexrazoxane in the development of secondary malignant neoplasms in patients who received dexrazoxane are reviewed. Based on the available data, dexrazoxane appears to be a safe and effective cardioprotectant in children, and it does not appear to alter overall survival times in children with cancer. Continued follow-up from previous trials is needed to determine the long-term effect of dexrazoxane on cardiac outcomes and quality of life.

PMID:
21051660
PMCID:
PMC3227904
DOI:
10.1634/theoncologist.2010-0162
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center